Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 142.77
ATHX's Cash to Debt is ranked higher than
73% of the 1443 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. ATHX: 142.77 )
ATHX' s 10-Year Cash to Debt Range
Min: 0.12   Max: No Debt
Current: 142.77

Equity to Asset 0.73
ATHX's Equity to Asset is ranked higher than
76% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ATHX: 0.73 )
ATHX' s 10-Year Equity to Asset Range
Min: -4.69   Max: 1
Current: 0.73

-4.69
1
F-Score: 2
Z-Score: -7.23
M-Score: 99999999.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1787.55
ATHX's Operating margin (%) is ranked higher than
54% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -95.34 vs. ATHX: -1787.55 )
ATHX' s 10-Year Operating margin (%) Range
Min: -1787.55   Max: -128.77
Current: -1787.55

-1787.55
-128.77
Net-margin (%) -1360.57
ATHX's Net-margin (%) is ranked higher than
55% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -77.05 vs. ATHX: -1360.57 )
ATHX' s 10-Year Net-margin (%) Range
Min: -1540.94   Max: -127.27
Current: -1360.57

-1540.94
-127.27
ROE (%) -86.21
ATHX's ROE (%) is ranked higher than
58% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. ATHX: -86.21 )
ATHX' s 10-Year ROE (%) Range
Min: -1459900   Max: -45.44
Current: -86.21

-1459900
-45.44
ROA (%) -59.24
ATHX's ROA (%) is ranked higher than
58% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. ATHX: -59.24 )
ATHX' s 10-Year ROA (%) Range
Min: -1459900   Max: -41.79
Current: -59.24

-1459900
-41.79
ROC (Joel Greenblatt) (%) -2174.49
ATHX's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 1411 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. ATHX: -2174.49 )
ATHX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1397000   Max: -1240.32
Current: -2174.49

-1397000
-1240.32
Revenue Growth (3Y)(%) -64.60
ATHX's Revenue Growth (3Y)(%) is ranked higher than
56% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. ATHX: -64.60 )
ATHX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 41.2
Current: -64.6

0
41.2
EBITDA Growth (3Y)(%) -14.70
ATHX's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 828 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. ATHX: -14.70 )
ATHX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -10.7
Current: -14.7

EPS Growth (3Y)(%) -19.30
ATHX's EPS Growth (3Y)(%) is ranked higher than
67% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ATHX: -19.30 )
ATHX' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -4.1
Current: -19.3

» ATHX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ATHX Guru Trades in Q1 2014

George Soros 157,000 sh (New)
Chuck Royce 929,000 sh (New)
Jean-Marie Eveillard 2,985,414 sh (-29.05%)
Jim Simons 30,500 sh (-91.18%)
» More
Q2 2014

ATHX Guru Trades in Q2 2014

Jean-Marie Eveillard 3,585,414 sh (+20.10%)
George Soros Sold Out
Jim Simons Sold Out
Chuck Royce 865,000 sh (-6.89%)
» More
Q3 2014

ATHX Guru Trades in Q3 2014

Chuck Royce Sold Out
Jean-Marie Eveillard 1,197,796 sh (-66.59%)
» More
Q4 2014

ATHX Guru Trades in Q4 2014

Jean-Marie Eveillard 712,500 sh (-40.52%)
Jean-Marie Eveillard 712,500 sh (-40.52%)
» More
» Details

Insider Trades

Latest Guru Trades with ATHX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 17.36
ATHX's Forward P/E is ranked higher than
96% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ATHX: 17.36 )
N/A
P/B 4.80
ATHX's P/B is ranked higher than
69% of the 1612 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. ATHX: 4.80 )
ATHX' s 10-Year P/B Range
Min: 0.18   Max: 25.25
Current: 4.8

0.18
25.25
P/S 63.88
ATHX's P/S is ranked higher than
53% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 37.64 vs. ATHX: 63.88 )
ATHX' s 10-Year P/S Range
Min: 1.16   Max: 320
Current: 63.88

1.16
320
Current Ratio 5.81
ATHX's Current Ratio is ranked higher than
77% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.39 vs. ATHX: 5.81 )
ATHX' s 10-Year Current Ratio Range
Min: 0.47   Max: 12.58
Current: 5.81

0.47
12.58
Quick Ratio 5.81
ATHX's Quick Ratio is ranked higher than
78% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. ATHX: 5.81 )
ATHX' s 10-Year Quick Ratio Range
Min: 0.47   Max: 12.58
Current: 5.81

0.47
12.58
Days Sales Outstanding 156.08
ATHX's Days Sales Outstanding is ranked higher than
71% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. ATHX: 156.08 )
ATHX' s 10-Year Days Sales Outstanding Range
Min: 20.54   Max: 156.08
Current: 156.08

20.54
156.08

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.50
ATHX's Price/Net Cash is ranked higher than
89% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 107.00 vs. ATHX: 5.50 )
ATHX' s 10-Year Price/Net Cash Range
Min: 0.33   Max: 10
Current: 5.5

0.33
10
Price/Net Current Asset Value 5.50
ATHX's Price/Net Current Asset Value is ranked higher than
88% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. ATHX: 5.50 )
ATHX' s 10-Year Price/Net Current Asset Value Range
Min: 0.32   Max: 9.62
Current: 5.5

0.32
9.62
Price/Tangible Book 4.90
ATHX's Price/Tangible Book is ranked higher than
79% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. ATHX: 4.90 )
ATHX' s 10-Year Price/Tangible Book Range
Min: 0.27   Max: 23.17
Current: 4.9

0.27
23.17
Price/Median PS Value 16.50
ATHX's Price/Median PS Value is ranked higher than
65% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. ATHX: 16.50 )
ATHX' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 19.75
Current: 16.5

0.18
19.75
Earnings Yield (Greenblatt) -35.60
ATHX's Earnings Yield (Greenblatt) is ranked lower than
62% of the 1398 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ATHX: -35.60 )
ATHX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -35.6   Max: 17247.5
Current: -35.6

-35.6
17247.5

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:4LS.Germany,
Athersys Inc was incorporated in Delaware on October 24, 1995. On June 8, 2007, it merged with a wholly owned subsidiary of BTHC VI, Inc., a Delaware corporation, and, on August 31, 2007, BTHC VI, Inc. changed its name to Athersys, Inc. It is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates. The Companys current product development portfolio consists of MultiStem, a patented and proprietary stem cell product that it is developing as a treatment for multiple disease indications, and that is currently being evaluated in two ongoing clinical trials. In addition, it is developing pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy or other forms of excessive daytime sleepiness. Its business objective is to discover, develop and commercialize novel therapeutic products for disease indications that represent areas of clinical need and commercial opportunity. Its partner, Pfizer Inc. is conducting Phase 2 clinical study of MultiStem cells. Myocardial infarction is one of the causes of death and disability in the United States. The Company is engaged in five programs including, Inflammatory Bowel Disease; Ischemic Stroke; Acute Myocardial Infarction; Hematopoietic Stem Cell Transplant / GvHD; Multistem. The Company partners with Pfizer, RTI, Angiotech and Bristol-Myers Squibb. It competes with Stem Cells Inc., Johnson & Johnson, Celgene Corporation, or Celgene, Advanced Cell Technology, Inc. The Company has 36 issued patents; 16 United States and 20 international. The Company and its related programs and the products are subject to government regulations.
» More Articles for ATHX

Headlines

Articles On GuruFocus.com
comment on ATHX Mar 02 2013 
Athersys Inc. (ATHX) CEO Bokkelen Gil Van buys 10,000 Shares Mar 18 2009 


More From Other Websites
Athersys to Host Shareholder Conference Call Apr 24 2015
Nasdaq stocks posting largest volume increases Apr 23 2015
Most active Nasdaq-traded stocks Apr 23 2015
The Zacks Analyst Blog Highlights: Amgen, Medicines, Athersys and Alnylam - Press Releases Apr 23 2015
Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampio & Athersys -... Apr 22 2015
Athersys Slumps as MultiStem Fails in Mid-Stage Study - Analyst Blog Apr 20 2015
Athersys (ATHX) Stock Continues to Decline Today on Stroke Therapy Trial Results Apr 20 2015
Athersys (ATHX) Stock Plummets to 52-Week Low as Stroke Therapy Fails Mid-Stage Trial Apr 17 2015
ATHERSYS ALERT: National Securities Law Firm Announces Investigation of Athersys Inc. Encourages... Apr 17 2015
ATHERSYS, INC / NEW Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 17 2015
Athersys stroke treatment fails study, shares slide Apr 17 2015
Athersys Announces Results From Phase 2 Study of MultiStem(R) Cell Therapy for Treatment of Ischemic... Apr 17 2015
Athersys stroke treatment fails mid-stage study Apr 17 2015
Athersys Announces Results From Phase 2 Study of MultiStem(R) Cell Therapy for Treatment of Ischemic... Apr 17 2015
Athersys to Host First Quarter Financial Results Call Apr 14 2015
Athersys to Host First Quarter Financial Results Call Apr 14 2015
Great Timing For Athersys, Other Stem Cell Companies Amidst Improving Regulatory Landscape Apr 13 2015
Athersys Future Hinges on Stem Cell Stroke Study Results Apr 13 2015
Athersys (ATHX) Worth Watching: Stock Gains 9.5% - Tale of the Tape Apr 09 2015
Athersys Phase 2 Ischemic Stroke Clinical Trial Results to be Presented at European Stroke... Apr 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK